AU Patent

AU2022277913A1 — Composition for treating autoimmune, alloimmune, inflammatory, and mitochondrial conditions, and uses thereof

Assigned to Individual · Expires 2023-11-16 · 3y expired

What this patent protects

Provided herein are compositions and methods for treating autoimmune, alloimmune, inflammatory, and mitochondrial conditions.

USPTO Abstract

Provided herein are compositions and methods for treating autoimmune, alloimmune, inflammatory, and mitochondrial conditions.

Drugs covered by this patent

mitapivat-sulfate (MITAPIVAT SULFATE)

Patent Metadata

Patent number: AU2022277913A1
Jurisdiction: AU
Classification: —
Expires: 2023-11-16
Drug substance claim: No
Drug product claim: No
Assignee: Individual
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.